The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings

The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings

As Lilly widens its lead in the obesity race, Novo is still racing to win back market share and restore investor confidence in its pipeline.

Novo Nordisk NVO Stock Prediction: $64 Bull, $32 Bear

Novo Nordisk raised its full-year outlook twice in 2026 and the stock is down 28% from its January peak. That combination is the whole investment case, in either direction. On 4 August the shares fell 6% on 47.5 million ADRs, the heaviest volume of the past year, and the headline everywhere was that the Wegovy pill had missed sales estimates. It had - by about 100 million Danish kroner, roughly $15 million on a 3.2 billion kroner line. A 3% shor…